Table 3.
Candidate variants showing a significant association with type 2 diabetes complications
| CHR | Closest gene | SNP | A1/A2 | MAF cases/controls | MAF European | OR (95% CI) | P-value | FDR | References |
|---|---|---|---|---|---|---|---|---|---|
| Neuropathies | |||||||||
| 6:35993906 | MAPK14, SLC26A8 | rs3761980 | G/A | 0.13/0.09 | 0.10 | 1.58 (1.08–2.33) | 1.94E-02 | 3.88E-02 | Meng et al. [49] |
| 6:35998388 | MAPK14 | rs80028505 | T/C | 0.13/0.09 | 0.11 | 1.58 (1.08–2.33) | 1.94E-02 | 3.88E-02 | Meng et al. [49] |
| Nephropathies | |||||||||
| 22:36657432 | APOL1 | rs136161 | G/C | 0.47/ 0.29 | 0.40 | 2.00 (1.40–2.86) | 1.41E-04 | 6.93E-03 | Iyengar et al. [50] |
CHR chromosome and base pair position in Human Genome build hg19, A1 minor allele, A2 major allele, OR odds ratio for the minor allele, CI confidence interval 95%, FDR false discovery rate by Benjamini & Hochberg method, MAF minor allele frequency, MAF European: minor allele frequency observed in the European population [31]